Organon & Co | OGN - Equity Capital And Reserves



Organon & Co reported $733M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Adcock Ingram Holdings ZAR 5.54B 131.19M Dec/2024
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Celltrion KRW 17.14T 298.25B Mar/2025
Cspc Pharmaceutical CNY 32.26B 2.59B Dec/2024
Dianthus Therapeutics USD 303.08M 49.4M Jun/2025
Divis Laboratories Ltd 149.69B 12.52B Mar/2025
Gilead Sciences USD 19.67B 596M Jun/2025
Glaxosmithkline GBP 14.35B 683M Jun/2025
Kangmei Pharma CNY 7.73B 546.26M Jun/2025
Knight Therapeutics CAD 773.91M 11.11M Sep/2024
Laboratorios Farma EUR 574.72M 6.82M Jun/2025
Malin Corporation EUR 193.2M 75M Dec/2024
Medical Developments International AUD 55.33M 9.6M Dec/2024
Merck USD 49.06B 725M Jun/2025
Neuren Pharmaceuticals AUD 363.9M 144.75M Dec/2024
Novartis USD 42.05B 1.99B Jun/2025
Organigram Holdings CAD 385.5M 61.85M Jun/2025
Organon & Co USD 733M 191M Jun/2025
Pharma Mar EUR 201.53M 4.06M Jun/2025
Qiagen NV USD 3.51B 97.61M Jun/2025
Sartorius EUR 2.66B 51.3M Jun/2025
Sino Biopharmaceutical CNY 31.96B 884.2M Dec/2024
Tilray USD 3.47B 5.16M Nov/2024